Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
tamoxifen
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(107)
News
Trials
Company:
Generic mfg.
Drug class:
Estrogen receptor antagonist
Related drugs:
‹
OP-1250 (7)
GDC-9545 (4)
Z-endoxifen hydrochloride (2)
OP-1250 (7)
GDC-9545 (4)
Z-endoxifen hydrochloride (2)
›
Associations
(107)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
HR positive + HER-2 negative
Male Breast Cancer
HR positive + HER-2 negative
Male Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
HR positive
Male Breast Cancer
HR positive
Male Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
ER positive
Male Breast Cancer
ER positive
Male Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
tamoxifen + medroxyprogesterone
Sensitive: A2 - Guideline
tamoxifen + medroxyprogesterone
Sensitive
:
A2
tamoxifen + medroxyprogesterone
Sensitive: A2 - Guideline
tamoxifen + medroxyprogesterone
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
tamoxifen + megestrol
Sensitive: A2 - Guideline
tamoxifen + megestrol
Sensitive
:
A2
tamoxifen + megestrol
Sensitive: A2 - Guideline
tamoxifen + megestrol
Sensitive
:
A2
ESR1 wild-type + HR positive
HER2 Positive Breast Cancer
ESR1 wild-type + HR positive
HER2 Positive Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
HR positive
Hormone Receptor Positive Breast Cancer
HR positive
Hormone Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
tamoxifen
Sensitive
:
B
tamoxifen
Sensitive: B - Late Trials
tamoxifen
Sensitive
:
B
ANIB1 overexpression
Breast Cancer
ANIB1 overexpression
Breast Cancer
tamoxifen
Resistant: B - Late Trials
tamoxifen
Resistant
:
B
tamoxifen
Resistant: B - Late Trials
tamoxifen
Resistant
:
B
TP53 mutation
Breast Cancer
TP53 mutation
Breast Cancer
tamoxifen
Resistant: B - Late Trials
tamoxifen
Resistant
:
B
tamoxifen
Resistant: B - Late Trials
tamoxifen
Resistant
:
B
HSD17B2 overexpression
Estrogen Receptor Positive Breast Cancer
HSD17B2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
tamoxifen
Sensitive
:
B
tamoxifen
Sensitive: B - Late Trials
tamoxifen
Sensitive
:
B
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
tamoxifen
Sensitive: B - Late Trials
tamoxifen
Sensitive
:
B
tamoxifen
Sensitive: B - Late Trials
tamoxifen
Sensitive
:
B
IGFBP7 overexpression
Estrogen Receptor Positive Breast Cancer
IGFBP7 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
tamoxifen
Sensitive
:
B
tamoxifen
Sensitive: B - Late Trials
tamoxifen
Sensitive
:
B
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C2 – Inclusion Criteria
tamoxifen
Sensitive
:
C2
tamoxifen
Sensitive: C2 – Inclusion Criteria
tamoxifen
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen + goserelin acetate
Sensitive: C2 – Inclusion Criteria
tamoxifen + goserelin acetate
Sensitive
:
C2
tamoxifen + goserelin acetate
Sensitive: C2 – Inclusion Criteria
tamoxifen + goserelin acetate
Sensitive
:
C2
EPRS1 expression
Estrogen Receptor Positive Breast Cancer
EPRS1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
FTO expression
Estrogen Receptor Positive Breast Cancer
FTO expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
CTDSP1 expression
Estrogen Receptor Positive Breast Cancer
CTDSP1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
BIN3 expression
Estrogen Receptor Positive Breast Cancer
BIN3 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
HR overexpression
Breast Cancer
HR overexpression
Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
RSF1 amplification
Estrogen Receptor Positive Breast Cancer
RSF1 amplification
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
tamoxifen
Resistant
:
C3
tamoxifen
Resistant: C3 – Early Trials
tamoxifen
Resistant
:
C3
AURKA overexpression
Estrogen Receptor Positive Breast Cancer
AURKA overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
tamoxifen
Resistant
:
C3
tamoxifen
Resistant: C3 – Early Trials
tamoxifen
Resistant
:
C3
NOS2 underexpression
Estrogen Receptor Positive Breast Cancer
NOS2 underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
tamoxifen
Sensitive: C3 – Early Trials
tamoxifen
Sensitive
:
C3
HPGD underexpression
Estrogen Receptor Positive Breast Cancer
HPGD underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
tamoxifen
Resistant
:
C3
tamoxifen
Resistant: C3 – Early Trials
tamoxifen
Resistant
:
C3
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen + CB-228
Sensitive: C3 – Early Trials
tamoxifen + CB-228
Sensitive
:
C3
tamoxifen + CB-228
Sensitive: C3 – Early Trials
tamoxifen + CB-228
Sensitive
:
C3
lncRNA DILA1 overexpression
Breast Cancer
lncRNA DILA1 overexpression
Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
tamoxifen
Resistant
:
C3
tamoxifen
Resistant: C3 – Early Trials
tamoxifen
Resistant
:
C3
CHID1 overexpression
Hormone Receptor Positive Breast Cancer
CHID1 overexpression
Hormone Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
tamoxifen
Resistant
:
C3
tamoxifen
Resistant: C3 – Early Trials
tamoxifen
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login